Media stories about Amedisys (NASDAQ:AMED) have trended positive on Tuesday, according to Alpha One Sentiment Analysis. Alpha One, a service of Accern, identifies positive and negative news coverage by analyzing more than 20 million blog and news sources in real-time. Alpha One ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Amedisys earned a news sentiment score of 0.36 on Alpha One’s scale. Alpha One also gave media headlines about the health services provider an impact score of 44 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
These are some of the media headlines that may have effected Alpha One’s scoring:
Amedisys (NASDAQ:AMED) opened at 59.91 on Tuesday. The company has a market capitalization of $2.02 billion, a P/E ratio of 44.38 and a beta of 1.43. Amedisys has a 52 week low of $34.58 and a 52 week high of $61.39. The firm has a 50 day moving average of $57.26 and a 200-day moving average of $49.10. Amedisys (NASDAQ:AMED) last announced its quarterly earnings data on Tuesday, May 2nd. The health services provider reported $0.47 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.41 by $0.06. Amedisys had a return on equity of 11.94% and a net margin of 2.93%. The business had revenue of $370.46 million for the quarter, compared to analysts’ expectations of $370.03 million. During the same period in the previous year, the business posted $0.33 EPS. On average, analysts forecast that Amedisys will post $2.07 earnings per share for the current year.
In related news, Director Jake L. Netterville sold 10,000 shares of the business’s stock in a transaction dated Friday, May 12th. The stock was sold at an average price of $60.00, for a total value of $600,000.00. Following the sale, the director now directly owns 77,499 shares in the company, valued at approximately $4,649,940. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Bruce D. Perkins bought 500 shares of Amedisys stock in a transaction on Thursday, May 25th. The shares were bought at an average cost of $59.69 per share, with a total value of $29,845.00. Following the acquisition, the director now directly owns 13,331 shares in the company, valued at $795,727.39. The disclosure for this purchase can be found here. Insiders sold a total of 56,828 shares of company stock worth $3,350,922 over the last 90 days. 2.80% of the stock is currently owned by company insiders. Amedisys Company Profile